TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04254991

Intervention type: DIAGNOSTIC_TEST
Intervention: ImmunoXpert™
Description: The ImmunoXpert™ technology employs a biochemical assay that measures a proprietary combination of three biomarkers of the immune system coupled with pattern recognition algorithms that classify the source of an infection as bacterial or viral

Intervention type: DIAGNOSTIC_TEST
Intervention: ImmunoXpert™
Description: The ImmunoXpert™ technology employs a biochemical assay that measures a proprietary combination of three biomarkers of the immune system coupled with pattern recognition algorithms that classify the source of an infection as bacterial or viral
Study: NCT02102204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Description: Etelcalcetide was supplied as a sterile, preservative-free, ready-to-administer aqueous solution.
Study: NCT03036215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PACT Experimental Arm
Description: The study will employ a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. The program provides 8 weeks of structured didactic and experiential training on exercises and cognitive- behavioral training to reduce risk factors that contribute to delayed recovery and enhance protective factors that have evidence of improving TMD pain.
Study: NCT00644891

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefdinir (Omnicef)
Description: 2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amoxicillin
Description: 2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
Study: NCT03572205

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LA
Description: The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LA
Description: The source of linoleic acid (LA) will be sunflower oil (62-63 % LA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ALA
Description: The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ALA
Description: The source of alpha-linolenic acid (ALA) will be camelina sativa oil (30-35 % ALA). The study diets will be isocaloric. The allowed weight change during the study is ± 2-3 %. The amount of supplementary oil will be calculated individually based on the calculated energy expenditure and adjusted, if necessary, during the study based on body weight measurements.
Study: NCT00369291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: keyhole limpet hemocyanin
Description: KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: tetanus toxoid
Description: Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
Study: NCT02206789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate1%,
Description: efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate1%,
Description: efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate1%, cyclosporine 2%
Description: penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate1%, cyclosporine 2%
Description: penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
Study: NCT03162913

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Strawberry
Description: 12g freeze-dried strawberry (powder), twice daily with water, for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12g red, strawberry-flavored powder, twice daily with water, for 90 days
Study: NCT01186172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol-lock therapy
Description: Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic-lock
Description: Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
Study: NCT00609531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Pill, 5-20mg once a day for twelve weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill once a day for twelve weeks
Study: NCT04502173

Intervention type: DEVICE
Intervention: Ellavi UBT
Description: The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).

Intervention type: DEVICE
Intervention: Ellavi UBT
Description: The study team will train all obstetric healthcare staff (i.e. obstetricians, midwives, medical officers, clinical officers) involved in PPH management at the participating healthcare facilities on use of the Ellavi UBT. This will be done to gather feedback from the healthcare workers (post-training and post-PPH) to understand the barriers to and facilitators of use in order to evaluate acceptability and feasibility among facilities providing different levels of care (level 4, level 5 (county), level 6 (tertiary)).
Study: NCT01243242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metadoxine (MG01CI)
Description: MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metadoxine (MG01CI)
Description: MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
Study: NCT00854113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGT0001474
Description: Oral ascending doses given daily as capsules for up to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match EGT0001474
Study: NCT04001530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Half Normal Saline 0.45% Infusion Solution Bag
Description: Randomization to half normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline 0.9% Infusion Solution Bag
Description: Randomization to normal saline
Study: NCT03263663

Intervention type: DRUG
Intervention: targeted substance according to the avatar model
Description: individualized second line treatment
Study: NCT03180632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Patient receives one or two tablet of 0,5mg Lorazepam according to body weight

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient receive one of two tablet of Placebo according to body weight
Study: NCT02061839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscream with visible light protection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sunscream
Study: NCT03844945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic Solution 0.01%
Description: Topical sterile ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic Solution 0.02%
Description: Topical sterile ophthalmic solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Netarsudil Ophthalmic Solution 0.04%
Description: Topical sterile ophthalmic solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Netarsudil Ophthalmic Solution Placebo
Description: Topical sterile ophthalmic solution
Study: NCT01095198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: offer of vaginal self collection
Description: Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2nd reminder letter for Pap testing
Description: Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2nd reminder letter for Pap testing
Description: Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
Study: NCT02565784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane
Description: Facial tissue augmentation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perlane
Description: Facial tissue augmentation
Study: NCT02113137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group 1: drug: chlorine dioxide
Description: First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: group 2: device: small tooth brush for tongue cleaning
Description: First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.~group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.~At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing.
Study: NCT01761162

Intervention type: DEVICE
Intervention: Patients with a ProMRI Pacemaker System
Description: Bradycardia Slow Heart Beat

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: MRI scan of head and lower back.
Study: NCT03767322

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Eligible patients will receive allopurinol 300 mg before and after coronary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Eligible patients will receive febuxostat 80 mg before and after coronary intervention

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible patients will receive before and after coronary intervention
Study: NCT02211391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Casein Protein
Description: The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-caloric placebo
Description: The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
Study: NCT03842930

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular embolization
Description: Endovascular embolization of the Lumbar Arteries

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Endovascular embolization
Description: Endovascular embolization of the Lumbar Arteries
Study: NCT03408795

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic distal gastrectomy
Description: Longitudinal testing of The Japanese Operative Rating Scale for Laparoscopic Distal Gastrectomy
Study: NCT04482946

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Assessment of fluid responsiveness
Description: The positive end-expiratory pressure test (PEEP-test) consisted of a transient increase of PEEP from 5 to 20 cm H2O for 120 seconds. The PEEP-test was interrupted if MAP decreased below 55 mm Hg and/or pulse contour cardiac index (PCCI) decreased below 1.5 L/min/m2. Mini-fluid challenge test (mFCT) consisted of rapid infusion of crystalloids 1.5 mL/kg during 120 seconds. Thereafter, all patients received fluid challenge (standard fluid challenge test, sFCT). During the sFCT, patients received 7 mL/kg of crystalloids within 10 minutes. Investigators performed monitoring of mean arterial pressure (MAP), SVV and PPVPiCCO using femoral artery (PiCCO2). Investigators also assessed PVVNK using radial artery and Nihon Kohden patient monitor. HLI (Hamilton G-5, Switzerland) and PVI (Masimo, USA) were assessed non-invasively, using finger probes.
Study: NCT02878187

Intervention type: DEVICE
Intervention: Doppler
Description: Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum

Intervention type: DEVICE
Intervention: Doppler
Description: Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:~The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum
Study: NCT00544700

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: 7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity

Intervention type: OTHER
Group type: OTHER
Intervention: no maintenance
Description: No treatment until progression
Study: NCT04193618

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative surgery for placenta accretta
Description: Uterine devasculrization and transverse compressing sutures before placental delivery
Study: NCT02687191

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05230907
Description: PF-05230907 IV bolus injection
Study: NCT01349049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: The drug product is available in capsule form, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: The drug product is available in capsule form, to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: The drug product is available in capsule form, to be taken orally.
Study: NCT04240977

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOBSCOTCH: Home-Based Self-Management and Cognitive Training Changes Lives
Description: Home-Based Self-Management and Cognitive Training Changes Lives (HOBSCOTCH) is a novel phone-based intervention that is enables acquisition of cognitive skills in line with problem solving therapy (PST), and is well suited for PWRE who have failed all other treatment alternatives. Sessions #2 through #7 focus on building patient's awareness for their own day-to-day memory problems, brainstorming, implementing and reviewing the outcomes of potential solutions they generate themselves using the PST framework. In each of these sessions, providers will assist patients in generating alternative solutions, in thinking through what the implementation of each strategy would entail, and in helping them review outcomes for adopted strategies to refine their approach for optimized adoption and generalization.
Study: NCT00775580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol 100mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol 100mg Tablets
Study: NCT00918814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102
Description: Subcutaneous Injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT01356550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917838
Description: single oral dose
Study: NCT02852382

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: morphine patient controlled analgesia
Description: End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine patient controlled analgesia
Description: End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine patient controlled analgesia
Description: End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.
Study: NCT03917602

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human amniotic membrane plug with vitrectomy
Description: using human amniotic membrane plug with vitrectomy to try to close large macular hole